Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2
Main Article Content
Keywords
deucravacitinib, psoriasis, clinical response, clinical outcomes, TYK2 inhibitor, POETYK
Abstract
N/A
References
2. Papp KA, et al. [poster] Presented at the 30th Congress of the European Academy of Dermatology and Venereology (EADV); September 29–October 2, 2021; virtual meeting.
3. Augustin M, et al. [poster] Presented at the American Academy of Dermatology (AAD) Annual Meeting; March 25–29, 2022; Boston, MA.
4. Armstrong AW, et al. Am J Clin Dermatol. 2019;20:155-164.
5. Loft ND, et al. Acta Derm Venereol. 2019;99:1224-1230.
6. Schäfer I, et al. Eur J Dermatol. 2010;20:62-67.
7. Thaçi D, et al. Dermatol Ther (Heidelb). 2022;12:495-510.
8. Price A, Cohen DE. Dermatitis. 2014;225:334-344.
9. Armstrong AW, et al. J Dermatol Treat. 2019;30:27-34
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.